2-[18F]FDG PET/CT Flare-up Phenomena Following T-Cell Engager Bispecific Antibody in Multiple Myeloma.
Bastien JametCaroline Bodet-MilinPhilippe MoreauFrançoise Kraeber-BodéréCyrille TouzeauPublished in: Clinical nuclear medicine (2023)
T-cell-redirecting bispecific antibodies represent a new standard of care for the treatment of triple-class refractory myeloma patients. Here, 2-[18F]FDG PET/CT imaging was performed on a 61-year-old woman with relapsed myeloma to determine metabolic response to talquetamab, a GPRC5DxCD3-bispecific antibody. At day 28, monoclonal (M) component assessment confirmed very good partial response (97% monoclonal protein reduction), whereas 2-[18F]FDG PET/CT imaging revealed early bone flare-up phenomena. At day 84, bone marrow aspirate, M-component assessment, and 2-[18F]FDG PET/CT demonstrated complete response, confirming the early flare-up hypothesis.
Keyphrases
- multiple myeloma
- bone marrow
- newly diagnosed
- high resolution
- end stage renal disease
- healthcare
- ejection fraction
- chronic kidney disease
- mesenchymal stem cells
- prognostic factors
- palliative care
- acute myeloid leukemia
- bone mineral density
- pain management
- small molecule
- single cell
- quality improvement
- diffuse large b cell lymphoma
- protein protein
- hodgkin lymphoma
- body composition
- chronic pain
- postmenopausal women
- health insurance
- replacement therapy
- affordable care act
- bone regeneration